Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative

European Journal of Pharmacology

Volumn 532, Issue 1-2, 2006, Pages 32-37

  Cherng, Shiou Chi ^a   Huang, Wen Hsin ^b   Shiau, Chia Yang ^b   Lee, An Rong ^b   Chou, Tz Chong ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Cyclic AMP; Glycoprotein IIb IIIa; PC 09; Platelet aggregation; Thromboxane B2

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; FIBRINOGEN RECEPTOR; PC 09; PYRIDAZINONE DERIVATIVE; THROMBIN; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE;

1-METHYL-3-ISOBUTYLXANTHINE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADENOSINE TRIPHOSPHATE; ALPROSTADIL; ANIMALS; ARACHIDONIC ACID; BLOOD PLATELETS; CALCIUM; COLLAGEN; CYCLIC AMP; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; INDOMETHACIN; NAPHTHALENES; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDAZINES; RABBITS; THROMBIN; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 33644526241     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.12.022     Document Type: Article

References (25)

1. Antiplatelet Trialists Collaborative overview of randomised trial of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
2. R.L. Bell, D.A. Kennerly, N. Stanford, and P.W. Majerus Diglyceride lipase: a pathway for arachidonic acid release from human platelets Proc. Natl. Acad. Sci. U. S. A. 76 1979 1790 1792
3. 2 activity specific for phosphatidic acid: a possible mechanism for the production of arachidonic acid in platelets J. Biol. Chem. 256 1981 5399 5403
4. M. Buerke, T. Cyrus, and H. Darius Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro Thromb. Res. 88 1997 89 98
5. T.C. Chou, and C.Y. Li Inhibitory mechanisms of dantrolene on platelet aggregation Thromb. Res. 96 1999 299 307
6. T.-C. Chou, C.-Y. Li, C.-C. Wu, M.-H. Yen, and Y.-A. Ding The inhibition by dantrolene of l-arginine transport and nitric oxide synthase in rat alveolar macrophages Anesth. Analg. 86 1998 1065 1069
7. T.-C. Chou, E. Fu, C.-J. Wu, and J.-H. Yeh Chitosan enhances platelet adhesion and aggregation Biochem. Biophys. Res. Commun. 302 2003 480 483
8. 2+-dependent translocation domain with homology to PKC and GAP Cell 65 1991 1043 1051
9. J.M. Dogne, S. Rolin, X. de Leval, P. Benoit, P. Neven, J. Delarge, P. Kolh, J. Damas, J.L. David, and B. Masereel Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531 Cardiovasc. Drug Rev. 19 2001 87 96
10. 2+ fluxes in human platelet membranes Biochimie. 69 1987 297 304
11. M.B. Feinstein, G.B. Zavoico, and S.P. Halenda Calcium and cyclic AMP: antagonistic modulators of platelet function G.L. Longerecker The platelets-Physiology and Pharmacology 1985 Academic Press Orlando 237 269
12. 2 as an amplifying signal for other agonists Am. J. Cardiol. 68 1991 11B 15B
13. V. Fuster, and J.H. Chesebro Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs Mayo Clin. Proc. 56 1981 185 195
14. A.G. Herman Rationale for the combination of anti-aggregating drugs Thromb. Res. 92 1998 S17 S21
15. M. Kroll, and A. Schager Biochemical mechanisms of platelet activation Blood 74 1989 1185 1195
16. T.H. Lejemtel, E. Keung, H.S. Ribner, R. Davis, J. Wexler, M.D. Blaufox, and E.H. Sonnenblick Sustained beneficial effects of oral amrinone on cardiac and renal function in patients Am. J. Cardiol. 45 1980 123 129
17. A.J. Marcus, and L.B. Safier Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis FASEB J. 7 1993 516 522
18. D.R. Phillips, I.F. Charo, and R.M. Scarborough GPIIb-IIIa: the responsive integrin Thromb. Res. 65 1991 359 362
19. 2+ influx into stimulated platelets Blood 66 1985 731 734
20. T.J. Rink, and S.O. Sage Calcium signaling in human platelets Annu. Rev. Physiol. 52 1990 431 449
21. D.W. Robertson, J.H. Krushinski, E.E. Beedle, V. Wyss, G.D. Pollock, H. Wilson, R.F. Kauffman, and J.S. Hayes Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6- tetrahydro-6-oxo-3-pyridazinyl)-2-indol-2-one J. Med. Chem. 29 1986 1832 1840
22. Z.M. Ruggeri Platelets in atherothrombosis Nature Med. 8 2002 1227 1234
23. J.R. Sheu, G. Hsiao, M.Y. Shen, T.H. Fong, Y.W. Chen, C.H. Lin, and D.S. Chou Mechanisms involved in the antiplatelet activity of magnesium in human platelets Br. J. Haematol. 119 2002 1033 1041
24. M. Tendera, and W. Wojakowski Role of antiplatelet drugs in the prevention of cardiovascular events Thromb. Res. 110 2003 355 359
25. G. Vizcaino-Salazar Platelet physiology. Advances in platelet reactivity Rev. Invest. Clin. 35 1994 41 62